TREM2 Signaling and Alzheimer's Disease: Experimental Modulators, Progress, and Challenges.
- 1School of Medicine, Creighton University, Phoenix, AZ, USA.
- 2Department of Pharmacology and Neuroscience, Texas Tech University Health Sciences Center, Lubbock, TX, USA.
- 3Department of Neurology, Barrow Neurological Institute, Phoenix, AZ, USA.
Abstract
Alzheimer's Disease (AD) is the leading cause of dementia worldwide, with a growing global burden and limited disease-modifying therapeutic options. The transmembrane receptor termed triggering receptor expressed on myeloid cells 2 (TREM2), which is mainly expressed by myeloid cells, has emerged as a target of interest in AD due to its role in modulating microglia functions, including cholesterol metabolism, phagocytosis of amyloid-beta (Aβ), inflammatory signaling, and innate immune neuronal protection. Genetic research has also shown that partial loss-of-function mutations in the TREM2 gene, particularly the R47H and R62H variants, substantially increase the risk of late-onset AD, further underscoring the therapeutic rationale for enhancing TREM2 signaling to combat the disease. Therapeutic strategies targeting TREM2 have exponentially increased in recent years, spanning monoclonal antibodies (mAbs) with distinct epitopes and mechanisms of receptor modulation, orally bioavailable small-molecule drugs capable of penetrating the blood-brain barrier (BBB), and upstream mechanisms targeting the shedding of the TREM2 ectodomain. Early clinical trials have revealed that target engagement does not translate directly into clinical benefit in patients, highlighting knowledge gaps in the timing of intervention, patient selection, dose optimization, and the complex dichotomy of TREM2 signaling, in which both insufficient and excessive activation may be detrimental to AD patients. Nonetheless, the continued advancement of therapeutics into clinical trials reflects the confidence in the underlying scientific rationale. This narrative review summarizes the current understanding of wild-type and variant TREM2 signaling in AD pathogenesis, evaluates the preclinical and clinical evidence supporting each class of TREM2-targeted therapeutic strategies, and discusses the challenges, emerging insights, and future directions that could shape the next generation of TREM2-based interventions for AD.
Related
- Alzheimer's Disease Detection via Large Pre-Trained Speech and Language Models: Taxonomy, Progress, and Open Challenges
- Glymphatic Dysfunction Across Neurological Disorders: Links to Neurodegeneration, Inflammaging, Gut–Brain Signaling, and Physiological Modulators
- De Novo Linear Peptides as Potential Recognition Elements and/or Aggregation Modulators of Amyloid-β42 in Alzheimer’s Disease
- The application progress of artificial intelligence in the diagnosis of Alzheimer’s disease
- Coumarins as modulators of autophagy and PI3K/mTOR signaling: implications for next-generation cancer therapies
BibTeX
@article{sayegh2026trem2,
title = {{TREM2 Signaling and Alzheimer's Disease: Experimental Modulators, Progress, and Challenges.}},
author = {Mark Sayegh and Katia Azarfar and Ellie Marie Reyna and Jessica Marianne Kennedy and Marwan N Sabbagh and Boris Decourt},
journal = {Drug design, development and therapy},
year = {2026},
month = oct,
doi = {10.2147/dddt.s611558},
url = {https://europepmc.org/article/MED/42953588},
note = {CC BY-NC},
}
RIS
TY - JOUR
TI - TREM2 Signaling and Alzheimer's Disease: Experimental Modulators, Progress, and Challenges.
AU - Mark Sayegh
AU - Katia Azarfar
AU - Ellie Marie Reyna
AU - Jessica Marianne Kennedy
AU - Marwan N Sabbagh
AU - Boris Decourt
PY - 2026
DA - 2026/10/23
JO - Drug design, development and therapy
DO - 10.2147/dddt.s611558
UR - https://europepmc.org/article/MED/42953588
AB - Alzheimer's Disease (AD) is the leading cause of dementia worldwide, with a growing global burden and limited disease-modifying therapeutic options. The transmembrane receptor termed triggering receptor expressed on myeloid cells 2 (TREM2), which is mainly expressed by myeloid cells, has emerged as a target of interest in AD due to its role in modulating microglia functions, including cholesterol metabolism, phagocytosis of amyloid-beta (Aβ), inflammatory signaling, and innate immune neuronal protection. Genetic research has also shown that partial loss-of-function mutations in the TREM2 gene, particularly the R47H and R62H variants, substantially increase the risk of late-onset AD, further underscoring the therapeutic rationale for enhancing TREM2 signaling to combat the disease. Therapeutic strategies targeting TREM2 have exponentially increased in recent years, spanning monoclonal antibodies (mAbs) with distinct epitopes and mechanisms of receptor modulation, orally bioavailable small-molecule drugs capable of penetrating the blood-brain barrier (BBB), and upstream mechanisms targeting the shedding of the TREM2 ectodomain. Early clinical trials have revealed that target engagement does not translate directly into clinical benefit in patients, highlighting knowledge gaps in the timing of intervention, patient selection, dose optimization, and the complex dichotomy of TREM2 signaling, in which both insufficient and excessive activation may be detrimental to AD patients. Nonetheless, the continued advancement of therapeutics into clinical trials reflects the confidence in the underlying scientific rationale. This narrative review summarizes the current understanding of wild-type and variant TREM2 signaling in AD pathogenesis, evaluates the preclinical and clinical evidence supporting each class of TREM2-targeted therapeutic strategies, and discusses the challenges, emerging insights, and future directions that could shape the next generation of TREM2-based interventions for AD.
SN - 1177-8881
ER -